Asivatrep for Eczema: Why Two Clear-Skin Definitions Produced Different Response Rates
Two true percentages can answer different questions
When an eczema trial reports both 36.0% and 20.3%, one number may not be an error. The percentages can use different definitions of response. Asivatrep's CAPTAIN-AD study is a useful example because reaching clear or almost-clear skin and improving by a specified number of grades were not the same endpoint.
An eight-week, vehicle-controlled comparison
The CAPTAIN-AD primary report, published online in 2021 and in a 2022 journal issue, enrolled 240 people aged at least 12 years with mild-to-moderate atopic dermatitis. Participants were randomized 2:1 to 1% asivatrep cream or vehicle twice daily for eight weeks. Asivatrep targets TRPV1; that research mechanism is not a recommendation to experiment with other products affecting skin sensations.
| Result | What it means |
|---|---|
| Clear or almost clear, IGA 0/1 | 36.0% active versus 12.8% vehicle at week eight; p < .001. |
| The stricter IGA improvement result | 20.3% versus 7.7% achieved at least two points of improvement; p = .01. |
| Mean EASI reduction | 44.3% versus 21.4% at week eight. |
| Mean itch VAS change | −2.3 versus −1.5; the between-group difference in mean changes is 0.8 points. |
The starting severity affects what a threshold means
An IGA score is an ordered clinical rating. A person starting with mild disease has a different path to almost-clear status from someone starting with a higher score. Requiring a two-grade improvement adds a condition that can exclude some people who reach the same final state. That is why the two response figures should remain separate, rather than selecting whichever makes the intervention appear strongest.
The stricter result is not a correction that makes the original primary endpoint disappear. Both deserve accurate labeling. Our study-results guide explains how endpoint definitions shape comparisons. The distinction between itch and rash scoring is relevant too: the 0.8-point difference in average itch changes is not an 80% benefit or a guarantee of itch elimination.
What this trial cannot answer
The study supports benefit relative to its vehicle under these conditions. It does not establish superiority over another prescription cream, suitability below age 12 or durable control over years. The abstract reports no significant safety issues, but 240 participants over eight weeks cannot rule out uncommon or delayed problems. A favorable group result should not be turned into universal tolerance.
How to use the paper at an appointment
Bring the study name and ask whether a locally available, authorized product matches it. A publication does not by itself establish availability, approval or instructions in your country. Ask which outcome matters for you: fewer visible lesions, less itch or better sleep and recovery. A short record can make that goal measurable without relying on the most impressive percentage in a headline.
Review the treatment plan with a dermatologist using current eczema guidance. Keep prescribed care in place while discussing alternatives. Mechanism names, clinical trial results and product instructions each answer a different question; none should be substituted for the others.
The separate role of daily moisture care
Dr. Arsy #003 4 oz moisturizer is a cosmetic product for hydration, moisture-barrier support and dry-skin comfort. It is not an eczema medicine, and these studies did not evaluate it. Its sports editorial image does not imply efficacy comparable to a prescription treatment. Discuss product suitability for children or actively inflamed skin with a clinician.
A related evidence question
For a different definition requiring both a clear-skin score and a two-grade improvement, see the current difamilast label's trial table.